Scarica l'app Stockscreener
261.77
1.81%
4.65
Dopo l'orario di chiusura:
261.39
-0.38
-0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Stock Rises as Management Details Pipeline Momentum at Wells Fargo Healthcare Conference - TIKR.com
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock? - finance.yahoo.com
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax Bio - Barchart.com
Endometriosis Market Analysis 2036: Industry Trends, Market Size, and Emerging Therapeutic Developments – DelveInsight | AbbVie, Kissei Pharma, Theramex, Hope Medicine, TiumBio, Viramal, Organon - Barchart.com
AbbVie Seeks To Nix Health Orgs' 'New Theory' In 340B Row - Law360
Can AbbVie (NYSE:ABBV) Defend Its Dividend Appeal? - Kalkine Media
Is AbbVie Stock Actually Overpriced? - Yahoo Finance
AbbVie’s ECLIPSE Migraine Trial Completes, Setting Up a New Catalyst for ABBV - TipRanks
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next - qz.com
Yarrow brings in more cash; AbbVie drug succeeds in menstrual migraine trial - Endpoints News
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s - Zacks Investment Research
What's Going On With AbbVie Stock Friday? - Benzinga
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study - Yahoo Finance
AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win - Yahoo Finance
AbbVie extends migraine leadership with positive Phase III atogepant results - thepharmaletter.com
AbbVie stock heads into the open after a 1.6% gain - ad-hoc-news.de
AbbVie declares $1.73 quarterly dividend payable Nov 16 to shareholders of record Oct 15 - Pluang
AbbVie, Eli Lilly Place Multi-Billion-Dollar Bets on Immunology Drugs in Race for Next Blockbuster - finance.biggo.com
AbbVie Declares Quarterly Dividend - Investing News Network
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Share Price Today (ABBV) | Live Chart, News & Stock Market - TechGraph
Abbvie Declares Quarterly Dividend, Payable on November 16, 2026 - marketscreener.com
AbbVie declares quarterly dividend of $1.73 per share - Investing.com
AbbVie declares quarterly dividend of $1.73 per share By Investing.com - Investing.com India
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Gains as Qulipta Opens a New Migraine Market - Yahoo! Finance Canada
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine - Investing News Network
AbbVie reports positive Phase 3 migraine trial results - grafa.com
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days - Benzinga
AbbVie Inc. stock gains as atogepant trial success and HSBC target hike reinforce growth story - ad-hoc-news.de
ABBV Maintained by HSBC -- Price Target Raised to $315 - GuruFocus
AbbVie's menstrual migraine treatment meets late-stage study goal - Reuters
Why Has AbbVie Gone Quiet About Humira? - Trefis
ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie (Pending:ADRX) - Seeking Alpha
AbbVie’s migraine treatment meets late-stage study goal - 1450 AM 99.7 FM WHTC
AbbVie reports positive phase 3 trial for menstrual migraine drug By Investing.com - Investing.com Canada
No treatment is approved for menstrual migraine. AbbVie’s drug cut migraine days in a trial. - Stock Titan
UChicago Medicine names Kimyatta Washington Chief Operating Officer of AbbVie Foundation Cancer Pavilion | Newswise - Newswise
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga
Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth? - Yahoo Finance
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference - TradingView
AbbVie at Wells Fargo healthcare conference: growth beyond immunology By Investing.com - Investing.com UK
ABBV: Immunology, oncology, and neuroscience pipelines advance with strong data and strategic investments - TradingView
AbbVie stock slips as Q2 revenue rises 10.2 percent - ad-hoc-news.de
AbbVie issues US$10 billion to fund Apogee acquisition - fi-desk.com
AbbVie stock heads into the open after a 2.99 percent drop - ad-hoc-news.de
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Apogee Therapeutics (NASDAQ: APGE) leaves Nasdaq in AbbVie cash buyout - Stock Titan
Why Did AbbVie (NYSE:ABBV) Just Close Its Biggest Deal In Years? - Kalkine Media
Is AbbVie Stock Too Reliant On Skyrizi? - Trefis
AbbVie Inc. stock edges lower as investors weigh strong earnings and higher analyst targets - ad-hoc-news.de
BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $282 - Moomoo
BofA Securities Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $282 - Moomoo
BofA raises Abbvie stock price target on Apogee deal close - investing.com
BofA raises Abbvie stock price target on Apogee deal close By Investing.com - Investing.com India
AbbVie’s Next Skyrizi Catalyst Lands This Fall. Here’s What’s at Stake for the Stock - TIKR.com
AbbVie Inc. (ABBV) Stock Analysis: Exploring Growth Potential Amidst A Solid 7.85% Upside - DirectorsTalk Interviews
What Does Friday’s Close Mean for AbbVie (NYSE:ABBV) and NYSE? - Kalkine Media
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):